Callan Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

Callan Family Office’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.98M	Sell	9,036 -56	-0.6%	-$42.9K	0.16%	138
2025 Q4	$7.02M	Buy	9,092 +2,348	+35%	+$1.59M	0.15%	133
2025 Q3	$3.79M	Buy	6,744 +704	+12%	+$398K	0.12%	177
2025 Q2	$3.17M	Buy	6,040 +4,135	+217%	+$2.31M	0.1%	213
2025 Q1	$1.21M	Buy	1,905 +336	+21%	+$231K	0.09%	190
2024 Q4	$1.12M	Buy	+1,569	New	+$1.32M	0.07%	229
2023 Q2	–	Sell	-786	Closed	-$646K	–	145
2023 Q1	$646K	Buy	+786	New	+$593K	0.16%	82

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Callan Family Office's REGN Position: Q1 2026 in Review

Callan Family Office reduced its Regeneron Pharmaceuticals (REGN) stake by 0.62% in Q1 2026, selling an estimated $42.9K and leaving 9,036 shares worth $6.98M. The position accounts for 0.16% of the portfolio, ranked #138.

Callan Family Office first reported a position in REGN in Q1 2023 and has held it in 7 quarters since. The position peaked at $7.02M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Callan Family Office held 9,036 shares of Regeneron Pharmaceuticals worth $6.98M as of Q1 2026.
Callan Family Office sold 56 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $42.9K.
Regeneron Pharmaceuticals made up 0.16% of Callan Family Office's portfolio in Q1 2026, its #138 holding.
Callan Family Office first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
Callan Family Office's Regeneron Pharmaceuticals position peaked at $7.02M in Q4 2025.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.